Xylazine is rapidly emerging as a significant contaminant in the illicit drug supply, often found alongside synthetic opioids such as fentanyl. Its increasing presence is creating new challenges for clinical and toxicology testing laboratories.
One key issue is that xylazine is not detected in standard opioid screening methods. In overdose situations, naloxone reverses opioid effects but has no impact on xylazine. As a result, patients may not respond as expected, increasing the risk of severe outcomes.
This gap is driving a need for more reliable ways to detect xylazine.
To address this need, Medix Biochemica has introduced a new antibody and matching antigen conjugate for xylazine detection:
Designed as a pair, these products form critical components of competitive immunoassays.
The antibody and antigen conjugate have been characterized and tested in:
Fluorescence immunoassays
These widely used formats provide a solid starting point for assay development.
As xylazine becomes more common alongside substances such as fentanyl and other drugs of abuse, testing requirements continue to evolve.
Having reliable detection tools in place is increasingly important to maintain accurate and meaningful results.
With Medix Biochemica’s new xylazine reagents, you can:
Develop assays targeting a growing and critical analyte
Support sensitive detection of xylazine and its main metabolite
Samples are available to support your assay development.
Order Samples:
Explore performance data: Xylazine mAb-conjugate Poster
Get in touch to find out what Medix Biochemica can do for you